CANCER BUZZ
CANCER BUZZ features fresh perspectives on hot topics in oncology care delivery. CANCER BUZZ is where stakeholders from the front lines of care to the C-suite, from research to the registry, from chairside to benchside, talk about top-of-mind questions and real-world impact.
info_outline
Real-World Oncology Decentralized Trials
08/20/2026
Real-World Oncology Decentralized Trials
Decentralized clinical Trials (DCTs) bring some or all elements of a clinical trial closer to patients. Consent, screening, treatment administration, and more can be administered through digital technologies and local health care providers, expanding accessibility for patients who face barriers to participation in traditional single site trials. In this episode, CANCER BUZZ speaks with Erin Pierce, MSN, APRN, FNP-C, Associate Clinical Investigator and Nurse Practitioner at HonorHealth Research Institute, and Kristen Kipping-Johnsson, MPH, Director of Network Research Operations at the University of Chicago, about how each of their cancer programs are approaching DCT implementation. Their discussion explores how decentralized components, such as community-based treatment delivery, centralized research infrastructure, and hybrid trial designs, can increase participation opportunities for patients in both community and academic settings. Guests: Erin Pierce, MSN, APRN, FNP-C Associate Clinical Investigator Nurse Practitioner HonorHealth Research Institute Scottsdale, AZ Kristen Kipping-Johnson, MPH Director of Network Research Operations University of Chicago Chicago, IL “APPs are really poised to step into that role [of investigator] and help, not take the place of physicians, but work alongside our physician colleagues and enable us to expand the abilities of research.” —Erin Pierce, MSN, APRN, FNP-C “Quality of life, being able to keep patients treated closer to home, allow them to stay with the physician that diagnosed them...Those are the things that are really important to me when it comes to decentralization.” —Kristen Kipping-Johnson, MPH Resources This podcast was created in partnership with the Decentralized Trials & Research Alliance, with support from Eli Lilly and Company, Gilead Sciences, and Merck.
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42494720
info_outline
The Real Cost of Cancer: Financial Toxicity, Transportation Challenges, and Access Gaps
08/19/2026
The Real Cost of Cancer: Financial Toxicity, Transportation Challenges, and Access Gaps
In this episode of Oncology Unscripted, hosts Mark Liu and Deirdre Saulet speak with Karen Winkfield, MD, PhD, a radiation oncologist and Associate Director of the Vanderbilt-Ingram Cancer Center, about her decades-long passion for community outreach and engagement to bring curative cancer treatment to underserved populations. Dr. Winkfield discusses the heavy financial burden of cancer and the need for policymakers and institutions to truly care for and prioritize the health of the American people. She also emphasizes the importance of “asset mapping” for healthcare administrators to take stock of the resources at their disposal and going out into the community to speak directly with people about what needs are not being met. “Policy is important for thinking about how we move the needle forward in cancer care. But it's not just policy on the national level or at the state level; it's actually institutional policy as well. And that's where access to care becomes personal for providers...What are the things that we can do as oncologists or...healthcare administrators to really ensure that we're taking good care of the communities we say we're there for?” – Karen Winkfield, MD, PhD Guest: Karen Winkfield, MD, PhD Radiation Oncologist Associate Director Vanderbilt-Ingram Cancer Center Nashville, Tennessee To submit a topic of discussion to the podcast, please email and . The 2026 Oncology Unscripted series is exclusively sponsored by Advarra. Resources
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42480730
info_outline
Closing the Gap in Medical Necessity Review With a Clinical Documentation Integrity Registered Nurse
08/18/2026
Closing the Gap in Medical Necessity Review With a Clinical Documentation Integrity Registered Nurse
Revenue cycle operations teams are responsible for maintaining reimbursement integrity and regulatory compliance across a rapidly expanding oncology service line. Increasing payer scrutiny—particularly for high-cost oncology therapies—has created significant operational strain, treatment delays, and administrative burden for providers. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Lacy Sheets, MBA, Director of Patient Financial Navigation at St. Luke’s Cancer Institute, about her program’s development and implementation of a Clinical Documentation Integrity Registered Nurse role. Embedded within revenue cycle operations, this role partners directly with physicians, financial navigators, pharmacists, and others to ensure medical necessity documentation is accurate and compliant with payer requirements. “The whole goal of this [position] is for our patients to be treated...in a more timely fashion...and not have to worry about all of that authorization work, as well as try to eliminate that [burden for] our providers.” – Lacy Sheets, MBA Guest: Lacy Sheets, MBA Director of Patient Financial Navigation, St. Luke’s Revenue Cycle Operations St. Luke’s Regional Medical Center / St. Luke’s Cancer Institute Boise, Idaho Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42465190
info_outline
Utilizing APPs to Deliver Bispecific Antibodies in the Outpatient Setting
08/07/2026
Utilizing APPs to Deliver Bispecific Antibodies in the Outpatient Setting
Bispecific antibodies (BsAbs) continue to garner the interest of both academic and community cancer centers due to their rapid growth in FDA approvals and increasing use in hematologic malignancies and solid tumors. However, practical considerations such as treatment-related toxicities, choosing the right delivery model, and staffing constraints deter many programs from attempting to implement BsAbs. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Kate Kennedy, MSN, APRN, ACNP-BC, AOCNP, an Outpatient Hematology Advanced Practice Provider (APP) Team Lead at Vanderbilt-Ingram Cancer Center, about her program’s APP-led BsAb step-up dosing clinic. With APPs at the helm, this model enables efficient and specialty-expert management of therapies while optimizing physician resources. In addition, its adherence to step-up dosing protocols prioritizes patient safety and convenience while reducing inpatient resource utilization. “[It’s important to look] at what you need to spend money on, [make] sure that you're spending money on the right things, and then [look] for areas like space and staff that maybe have capacity that you can utilize in a little bit of a different way to deliver this care.” – Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNP Guest: Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNPOutpatient Hematology APP Team Lead Vanderbilt-Ingram Cancer Center Nashville, Tennessee Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42348755
info_outline
Between the Orders and the Infusion: The Patient Experience of Bispecific Antibodies
08/04/2026
Between the Orders and the Infusion: The Patient Experience of Bispecific Antibodies
As bispecific antibodies (BsAbs) become more integrated into oncology care, much of the focus has been placed on clinical protocols and operational readiness. However, less attention has been paid to the patient and caregiver experience. In this episode, CANCER BUZZ explores how it feels physically and emotionally for patients to begin and continue BsAb therapy. Grounded in real-world insights, this discussion highlights the logistical and emotional challenges that arise during the step-up period and early treatment phases and identifies opportunities for care teams to better support patients throughout their journey. In partnership with HOPA and APSHO. This program was made possible with support from Johnson & Johnson and Genentech. Guest: Leslie Mader, RN, BSN, OCN Patient Care Coordinator, Bispecific Drug Therapy and IEC Therapy, Hematology/Stem Cell Transplant Vanderbilt Ingram Cancer Center “It decreased the amount of time they had to be in the clinic, you know, because a lot of these people we're getting them back to their regular lives where they can work, they can go to you know continue on with life. So anything that we can give that's in an injection, and anything that's targeted to decrease systemic reactions is better for the patient.” - Leslie Mader “They think, oh, this is great. I'm going to get through it with no problems. And then they get dose three or dose four, and they're like crap. You know, they get discouraged. But usually, you know, we have emergency drugs that we give them dexamethasone, and it usually resolves quickly.” - Lesie Mader Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42313240
info_outline
Centering Compassion in Cancer Care
07/29/2026
Centering Compassion in Cancer Care
In this episode of Oncology Unscripted, hosts Mark Liu and Deirdre Saulet speak with Arif Kamal, MD, Chief Patient Officer at the American Cancer Society (ACS). Dr. Kamal discusses his recent appointment to this inaugural role at ACS, leading into a conversation about how he expects the cancer care field to evolve. Namely, a shift for providers toward building a skillset for compassionate patient conversations, a shift toward self-administered treatment modalities whenever possible, and new payment models for multi-cancer early detection tests. Dr. Kamal also shares how ACS’s recently launched Access to Clinical Trials and Support program—an education-forward initiative designed is helping to reduce the challenges and barriers patients face when enrolling in clinical trials. “When you think about...the goal of cancer care...it’s about more and better days. It is a false choice to choose between one or the other...As we’re getting people to the other side [of treatment], are we leaving them financially devastated, significantly lonely, without support around them?” – Arif Kamal, MD Arif Kamal, MD Chief Patient Officer American Cancer Society To submit a topic of discussion to the podcast, please email and The 2026 Oncology Unscripted series is exclusively sponsored by Advarra. Resources
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42248810
info_outline
A Pharmacist-Led Care Model for Oncolytic Virus Treatment Delivery
07/23/2026
A Pharmacist-Led Care Model for Oncolytic Virus Treatment Delivery
Oncolytic viruses are a novel and effective way to treat cancers by infecting and destroying cancer cells, but clinical delivery necessitates creative strategies to account for the required safety protocols, deep-freeze storage, and rigorous clinical oversight. The University of North Carolina (UNC) Lineberger Comprehensive Cancer Center is a referral center for the only currently FDA-approved oncolytic virus therapy for cancer, talimogene laherparepvec, and its staff noticed that a common pain point for patients receiving this treatment is the extensive time spent in appointments. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Morgan Gwynn, PharmD, BCOP, CPP, an Oncology Clinical Pharmacist Practitioner at UNC Lineberger, about her program’s development of a pharmacist-led care model to make oncolytic virus treatments more efficient for patients and providers. By moving toxicity assessment, clinical review, and dose planning to pre-treatment telemedicine visits, the program reduced treatment time by more than 2 hours per session and helped decrease unnecessary clinic visits and drug waste. “Just because there’s one way that things are done, [that] doesn’t mean that’s the only way things can be done...Finding creative solutions that benefit...the patient, the physician, and our pharmacy...was key.” – Morgan Gwynn, PharmD, BCOP, CPP Guest: Morgan Gwynn, PharmD, BCOP, CPP Oncology Clinical Pharmacist Practitioner University of North Carolina Medical Center
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42193930
info_outline
The Urology-Oncology Partnership in ADCs
07/15/2026
The Urology-Oncology Partnership in ADCs
In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment option. To administer this ADC-based therapy alongside surgical intervention, multidisciplinary teams must prioritize collaborative workflows at all points of the treatment journey. In this episode, CANCER BUZZ speaks with Manojkumar Bupathi, MD, President of Rocky Mountain Cancer Centers, about how ADCs are reshaping the care model toward earlier, structured collaboration between urology and medical oncology. Guests: Manojkumar Bupathi, MD President Rocky Mountain Cancer Centers Co-Chair, GU Executive Committee Sarah Cannon Research Institute Denver, CO “The challenge wasn’t learning the drug itself. The challenge was how you integrate the regimen into your treatment paradigm.” —Manojkumar Bupathi, MD “There’s always this relationship that happens from the beginning and is maintained throughout the entire process.” —Manojkumar Bupathi, MD Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42105770
info_outline
A Team Approach to ADCs in Bladder Cancer
07/08/2026
A Team Approach to ADCs in Bladder Cancer
At the University of California, San Francisco (UCSF), the team treating patients with bladder cancer and other genitourinary malignancies utilizes a multidisciplinary team approach to ensure care is coordinated, personalized, and patient-centered. This is particularly important when administering antibody-drug conjugates, a promising tool for some patients with muscle-invasive bladder cancer that comes with a high risk of adverse events (AEs). In this episode, CANCER BUZZ speaks with Terence Friedlander, MD, and Iva Petrovchich Colón, NP, both part of the team treating bladder cancer at UCSF, about how their cancer program manages the toxicity profile of ADCs in order to prioritize patient outcomes and quality of life. Guests: Terence Friedlander, MD Robert and Virginia O'Reilly Family Professor of Medicine Chief of Hematology-Oncology, Zuckerberg San Francisco General Hospital UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA Iva Colón, NP Nurse Practitioner, Genitourinary Medical Oncology UCSF Health Genitourinary Medical Oncology Mission Bay San Francisco, CA “The median onset is in the mid 60s, and folks who are in their 60s are more mature, they may have more comorbidities, more medical problems, and we have to be really sensitive to that.” —Terence Friedlander, MD “It takes a village and having that having open and direct communication is key.” —Iva Colón, NP Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/42006925
info_outline
MDS: Low Risk Isn’t No Risk
06/30/2026
MDS: Low Risk Isn’t No Risk
Myelodysplastic syndromes (MDS), a rare category of bone marrow disorders that may develop into acute myeloid leukemia, are categorized into risk groups ranging from very low to very high risk. However, this language can be misleading to patients. Low risk (LR) does not equate to low impact or lack of urgency. In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, from Sidney Kimmel Comprehensive Cancer Center, and Christin Blair DeStefano, MD, FACP, from Walter Reed National Military Medical Center, about the importance of aligning language and terminology regarding LR-MDS across academic and community settings. These experts candidly discuss their own collaboration and the importance of early conversations with patients to align expectations on goals, disease trajectory, and treatment sequencing. Guests: Amy DeZern, MD, MHS Hematologist/Oncologist Director, Bone Marrow Failure and MDS Program Sidney Kimmel Comprehensive Cancer Center Baltimore, MD Christin Blair DeStefano, MD, FACP Hematologist/Oncologist Walter Reed National Military Medical Center Bethesda, MD “I really try and individualize [language] to a patient and their family, because I worry that sometimes the terminology ‘lower risk’ may not correctly convey the impact the disease is going to have on an individual human's life.” — Amy DeZern, MD, MHS “Frequent reassessment—questioning our patients about quality of life and if we're meeting the goals they have—should be something that's readily reassessed, especially in the lower risk space, every 2 to 3 months, just to make sure we don't put anybody on autopilot.” — Amy De Zern, MD, MHS “There's been such an explosion in understanding the molecular landscape of MDS and slicing and dicing it into different diseases that fall under the MDS umbrella. It has sometimes created a little bit of confusion.” — Christin Blair DeStefano, MD, FACP Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41905070
info_outline
Beyond Body Art: Restoring Wholeness Through Paramedical Tattooing
06/23/2026
Beyond Body Art: Restoring Wholeness Through Paramedical Tattooing
From the moment a woman learns that she has breast cancer, her life is forever changed—from the treatment challenges of chemotherapy, radiation, and surgery to the personal and emotional challenges of a change in identity, a loss of control, and physical self-acceptance. For many survivors, the difficult journey of emotional healing continues long after active treatment ends, and this phase deserves to be addressed with the same urgency and compassion as diagnosis and treatment. To dive into this defining moment of the cancer care continuum and learn how providers can support patients as they navigate vulnerable moments, CANCER BUZZ spoke with Taylor Keeney, an areola restoration tattoo artist, licensed esthetician, and owner of TayK Cosmetics, and her client Eraina Bartholomew, a survivor of breast cancer. Together, the guests explore the human side of cancer care, how paramedical tattooing bridges a critical gap in breast cancer survivorship care, and the importance of restoring not just physical health, but dignity and joy. “Unfortunately, cosmetics can be seen as superficial in today’s society, especially with women. But [paramedical tattooing] plays a big role in [survivors’] mental and emotional health, their psyche, [and] how they view themselves. It’s very symbolic to help them close that chapter of breast cancer and move forward in their life.” – Taylor Keeney “That experience changed my life. It meant so much to me...at the end of this journey, to find some sense of normalcy in feeling [complete and] like a whole woman...being able to look in the mirror and not cringe at myself.” – Eraina Bartholomew Guests: Taylor Keeney Areola Restoration Tattoo Artist Licensed Esthetician Owner TayK Cosmetics Eraina Bartholomew Breast Cancer Survivor Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41729020
info_outline
Bridging Radiation and Oncology in SCLC Care
06/19/2026
Bridging Radiation and Oncology in SCLC Care
Radiation therapy is a powerful and non-invasive tool in the management of small cell lung cancer (SCLC), but radiation oncologists are not always fully integrated into the care team. In this episode, CANCER BUZZ speaks with Charles B. Simone, II, MD, FASTRO, FACRO, FACR, chief medical officer of the New York Proton Center and radiation oncologist at Memorial Sloan Kettering Cancer Center, about strategies to improve collaboration between radiation and medical oncology. He discusses some of the biggest barriers and greatest rewards of enhancing this partnership and expanding access to radiation therapy for SCLC. Guest: Charles B. Simone, II, MD, FASTRO, FACRO, FACR Research Professor and Chief Medical Officer New York Proton Center Radiation Oncologist Memorial Sloan Kettering Cancer Center New York, NY “While we don't have large, randomized trials really telling us how the modalities should be sequenced, that really should be a discussion and personalized for each patient.” —Charles B. Simone, II, MD, FASTRO, FACRO, FACR “After a slow 20 years of limited progress, this last half a decade has seen dramatic progress for small cell, and with that, the multidisciplinary collaboration is even more important.” —Charles B. Simone, II, MD, FASTRO, FACRO, FACR Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41698305
info_outline
Championing Bispecific Antibodies in the VA
06/10/2026
Championing Bispecific Antibodies in the VA
Bispecific antibodies (BsAbs) are an emerging and fast-developing area of immunotherapy, particularly in the treatment of hematologic malignancies. However, access to this therapy remains limited, particularly for Veterans. Administrative hurdles and challenging adverse events have slowed adoption of BsAbs in the US Department of Veterans Affairs (VA). In this episode, CANCER BUZZ speaks with Nicholas Burwick, MD, hematologist in the Puget Sound VA Health Care System, about how his VA site tackled these challenges and made BsAbs available to its patient population through a collaborative hub-and-spoke model. Guest: Nicholas Burwick, MD President, Association of VA Hematology/Oncology Hematology and Bone Marrow Transplant Puget Sound VA Health Care System “We set expectations, we came up with a plan, and we didn’t have too many bispecific antibody patients at the same time. At least initially, we wanted some control.” — Nicholas Burwick, MD “The collaboration among different VA centers has been something that I’ve come to appreciate. We have a heme malignancy group, for example, so we can compare notes, work together, and in some cases even collaborate on VA initiative proposals or industry-sponsored clinical trials.” — Nicholas Burwick, MD Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41602355
info_outline
Data-Driven Toxicity Management for ADCs
06/03/2026
Data-Driven Toxicity Management for ADCs
Toxicities related to antibody-drug conjugates (ADCs) can significantly impact quality of life for patients with locally advanced or metastatic bladder cancer, but data-driven programs can help multidisciplinary teams manage some of the most challenging adverse events. In this episode, CANCER BUZZ speaks with Cindy Y. Jiang, MD, assistant professor at MD Anderson Cancer Center, about how her institution conducted and implemented research to aid management of rashes and peripheral neuropathy associated with the ADC enfortumab vedotin combined with pembrolizumab. Guest: Cindy Y. Jiang, MD Assistant Professor Department of GU Medical Oncology MD Anderson Cancer Center Houston, TX “It's important to assemble this team before you start on any sort of journey, because as oncologists, we're definitely not experts in skin rashes or neurological issues, and so you really need to rely heavily on those collaborators.” — Cindy Y. Jiang, MD Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41515910
info_outline
Advancing Cancer Care Worldwide: ACCC Global eXchange
05/27/2026
Advancing Cancer Care Worldwide: ACCC Global eXchange
The ACCC Global eXchange series is committed to highlighting cross-regional collaborations that advance cancer care delivery and workforce development nationwide. In this episode of CANCER BUZZ, Dr. Michael Cavnar discusses his humanitarian efforts in Zambia and why volunteering in this capacity is crucial and meaningful for US oncology providers. “The more you’re around people that are different than you, the more different perspectives you see. It creates a more open mind and a better world, because people understand each other better.” – Michael Cavnar, MD Guest: Michael Cavnar, MD GI Surgical Oncologist UK HealthCare/Markey Cancer Center Lexington, KY Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41438935
info_outline
Designing Care That Creates Value for Patients and the Health System
05/12/2026
Designing Care That Creates Value for Patients and the Health System
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, panel discussions, and peer-to-peer exchange focused on the most pressing issues in cancer care today. In this episode, CANCER BUZZ speaks with Misha Kaur, chief operating officer at Cureety, about her key takeaways as a member of the panel: Value-Based Care in Oncology: From Pilots to Scale. Kaur discusses the importance of keeping quality and affordability at the heart of value-based care, and how Cureety’s remote monitoring solution effectively captures nuanced patient insights in precision oncology care. “[Value-based care] was never meant to be a contract. The original spirit was [about] aligning incentives [and creating] better outcomes for patients. But in practice, over time...it can sometimes become just a contracting discussion [about] targets, benchmarking, reporting, utilization, [and] cost reduction.” – Misha Kaur Guest: Misha Kaur Chief Operating Officer Cureety Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41241695
info_outline
A Collaborative Approach to Health Policy Changes
05/11/2026
A Collaborative Approach to Health Policy Changes
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, panel discussions, and peer-to-peer exchange focused on the most pressing issues in cancer care today. In this episode, CANCER BUZZ speaks with Jay Seemann, vice president of market and access value at BeOne Medicines, about his key takeaways as a member of the panel: Health Policy: Provider Voices Outlook. Seemann addresses macro-level health care reform changes across all market segments, and the impact on manufacturers, providers’ choice of therapy, and patient access to care. “What we heard at the conference is that we all need to unite, come together, and come up with partnerships and solutions collectively versus independently.” – Jay Seemann Guest: Jay Seemann Vice President of Market And Access BeOne Medicines Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41241595
info_outline
Closing the Gap Between Innovation and Implementation: Strategic Partnerships in Oncology
05/05/2026
Closing the Gap Between Innovation and Implementation: Strategic Partnerships in Oncology
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, engaging panel discussions, and peer-to-peer exchange focused on the most pressing issues in cancer care today. In this episode, CANCER BUZZ speaks with Michele LeSueur, DBA, vice president of Sales and Marketing at Johnson & Johnson, about her key takeaways as a member of the final panel of the Summit: Strategic Partnerships: Creating a Thriving Innovation Oncology Ecosystem. Across the diverse panel of stakeholders, one theme consistently rang true: Innovation is happening very quickly in oncology, but the gap continues to widen between the inception and the implementation of these ideas into day-to-day patient care. Lesueur also comments on the importance of industry partners listening and understanding where friction might occur when launching a new treatment or delivery system. "It's not just about continuously generating breakthrough science or breakthrough treatment. That's only going to take us so far. We have to think about how to actually incorporate that and get it to the patients.” – Michele LeSueur, DBA Guest: Michele LeSueur, DBA Vice President of Sales and MarketingJohnson & Johnson Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41155355
info_outline
Becoming a Smart Consumer of AI as an Oncology Leader
05/04/2026
Becoming a Smart Consumer of AI as an Oncology Leader
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, engaging panel discussions, and peer-to-peer exchange focused on the most pressing issues in cancer care today. In this episode, CANCER BUZZ speaks with Ashley Johnson, MBA, chief innovation officer at LeanTaas, about her key takeaways as a member of the first panel of the Summit: AI in Oncology: Tools for Today, Breaking and Remaking for Tomorrow. Johnson reflects on the challenges oncology leaders face as they attempt to vet and adopt a flood of new AI tools in health care, as well as the importance of being an educated consumer in this space. “I hope oncology leaders took away [that] you can become a smart consumer of AI and AI tools even if you don’t fully understand AI and all of the buzzwords.” – Ashley Joseph, MBA Guest: Ashley Joseph, MBA Chief Innovation Officer LeanTaas Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/41141820
info_outline
BsAbs: Moving from Curiosity to Confidence
04/21/2026
BsAbs: Moving from Curiosity to Confidence
Indications for the use of bispecific antibodies (BsAbs) are rapidly increasing in oncology. While many cancer centers are keeping an eye on this developing field, curiosity must be transformed into proactive planning to avoid being caught unprepared as BsAb indications expand. In this episode, CANCER BUZZ speaks with Laura Kuzma, MSW, admin administrative director of FirstHealth Cancer Center and Oncology Services at FirstHealth Moore Regional Hospital, about the real-world lessons she has learned about governance considerations, ramp-up strategies, and workflows. She shares the importance of proactively building workflows, readiness plans, and cross-team communication pathways to safely operationalize BsAb therapy. Guest: Laura Kuzma, MSW Administrative Director, Oncology Services and Clinical Trials FirstHealth Moore Regional Hospital Pinehurst, NC “That was the biggest hesitancy: are we equipped to manage this type of care in this type of setting?” “My request to the hospital administrators was to allow me to put together a team across the hospital to fully explore the financial side as well as the medical management side.” “We had doctors in every area of the hospital on this. They cared about it, and I think it was exciting to them too. They felt like they were doing something meaningful, and their input was taken seriously.” Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/40956695
info_outline
Innovation in Action: Breaking Down the 2025 ACCC Impact Report
04/07/2026
Innovation in Action: Breaking Down the 2025 ACCC Impact Report
For 52 years, ACCC has brought together thousands of health care professionals from across the nation representing all disciplines in oncology. Today, with over 46,000 members, ACCC’s mission remains the same: to provide education, forums, and opportunities to promote the delivery of high-quality, equitable cancer care. Each year, the Association produces an ACCC Annual Report showcasing key educational programming and policy work it has produced for its member cancer programs and practices across the country. In this episode, CANCER BUZZ speaks with Meagan O’Neill, MS, executive director of ACCC, about the 2025 ACCC Impact Report, highlighting advancements in financial advocacy, patient-centered care for Veterans with cancer, and access to cutting-edge therapies like CAR T-cell therapy. “The most exciting thing about [the Impact Report] is it's a reflection of what's possible when the oncology community works together. Progress in cancer care is not going to happen through isolation. It's going to happen through collaboration, and that's what ACCC is here to support.” – Meagan O’Neill, MS Guest: Meagan O’Neill, MS Executive Director Association of Cancer Care Centers Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/40756030
info_outline
Transforming Palliative Care in Oncology
03/18/2026
Transforming Palliative Care in Oncology
In this episode of Oncology Unscripted, hosts Mark Liu and Deirdre Saulet speak with 2025 ACCC Innovator Award Winner Andrew Ambort, DO, a palliative care consulting physician at WellSpan Health. Dr. Ambort received the award for his team’s innovation “Adopting Machine Learning-Enabled Decision Support to Improve Oncology End-of-Life Outcomes,” which leveraged an existing module in the electronic health record to integrate a 12-month mortality risk into clinical workflows. He discusses the vision behind this initiative, plans for expansion into other specialties and service lines, and the human impact that early, integrated palliative care has had on WellSpan’s patient community. “[Caregivers] are so busy dealing with the chaos of end-of-life care...and then [they] get this bill at the end that surprises [them] too. It’s not the experience we want for anyone, especially patients with cancer.” – Mark Liu, MHA “Unfortunately, the bills don’t stop coming when people die...and it puts them right back in that [difficult] place. Being able to reduce that cost helps them grieve appropriately and get to a place where they [find acceptance] and prevent backsliding.” – Andrew Ambort, DO “The visibility is huge in terms of staying at the forefront of the oncology team’s mind...[and reminding them] this is a resource we need to be leveraging and bringing into the fold.” – Deirdre Saulet, PhD Andrew Ambort, DO Palliative Care Consulting Physician WellSpan Health To submit a topic of discussion to the podcast, please email and . Resources
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/40514565
info_outline
Streamlining Access to TIL Cell Therapy for Melanoma
03/03/2026
Streamlining Access to TIL Cell Therapy for Melanoma
Tumor-infiltrating lymphocyte (TIL) cell therapy is a promising option for patients with advanced melanoma, but logistical and referral challenges can be a barrier to care. In this episode, CANCER BUZZ speaks with Lilit Karapetyan, MD, MS, FACP, medical oncologist at Moffit Cancer Center and Research Institute, an authorized treatment center (ATC) for TIL cell therapy, and Raju Vaddepally, MD, hematologist-oncologist at Florida Cancer Specialists, a non-ATC, about the referral process. Both guests discuss the relationship between their cancer programs, offering actionable tips on how to streamline the identification and referral of melanoma patients for TIL therapy across institutions. Guests: Lilit Karapetyan, MD, MS, FACP Medical Oncologist Moffitt Cancer Center and Research Institute Tampa, FL Raju Vaddepally, MD Hematologist-Oncologist Florida Cancer Specialists Naples, FL “It is extremely important that providers think about this earlier, because the huge issue that we have with TIL therapy is that we get a lot of patients referred but unfortunately, they are no longer fit to proceed with the therapy.” - Lilit Karapetyan, MD, MS, FACP “Cancer care can be so fragmented and always requires multidisciplinary input, whether it be within the town or going to an academic center, so we do have a specialized department in which they handle all these referrals.” - Raju Vaddepally, MD Resources
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/40301565
info_outline
Policy in Practice: Change Hits the Clinic
02/17/2026
Policy in Practice: Change Hits the Clinic
Changing regulations are reshaping the practice of oncology. Issues such as prior authorization, shifting coverage policies, reporting mandates, and reimbursement certainty all affect how clinics must operate to provide the best care. In this episode, CANCER BUZZ speaks with 3 oncology professionals, representing different roles and regions of the country, about their experiences of how policy impacts care delivery. Martin Palmeri, MD, MBA, FASCO, medical oncologist at Messino Cancer Centers, Patricia Serna, MHS, PA-C, CGRA, APP area manager at Texas Oncology, and Gretchen Van Dyck, financial counselor at Green Bay Oncology, connect the dots between legislative intents and clinical realities. “When my patients see that their options for clinical trials are diminishing, or some of these clinical trials are shutting down, they lose hope.” - Martin Palmeri, MD, MBA, FASCO “Being able to work with the Texas Society of Clinical Oncology has given me that behind-the-scenes background of if we don't speak up, our patients are going to suffer.” Patricia Serna, MHS, PA-C, CGRA Guests: Patricia Serna, MHS, PA-C, CGRA APP Area Manager – APP Services Texas Oncology Dallas, TX Gretchen Van Dyck Financial Counselor II Green Bay Oncology Green Bay, WI Martin Palmeri, MD, MBA, FASCO Medical Oncologist Messino Cancer Centers Asheville, NC This podcast is part of the Oncology State Societies (OSS) Advocacy Engagement program, made possible with support from Johnson & Johnson. Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/40141095
info_outline
Addressing Psychosocial Distress With Psychedelic-Inspired Therapies
02/05/2026
Addressing Psychosocial Distress With Psychedelic-Inspired Therapies
As the number of patients and survivors of cancer grows each year, awareness of the disease’s emotional toll—including depression, anxiety, and deep existential distress—is increasingly recognized as a critical aspect of cancer care. In response, psychedelic-assisted therapy is gaining attention as a promising alternative to traditional mental health interventions, providing relief for some patients. To shed light on the patient experience with this treatment, CANCER BUZZ spoke with breast cancer survivor Judy Wight; Jennifer Bires, MSW, LCSW, OSW-C, FACCC, executive director of Life with Cancer and Patient Experience at Inova Health System; and Manish Agrawal, MD, cofounder and CEO of Sunstone Therapies, about the human side of psychedelic-assisted therapy, promising existing research, and how it can shape the future of psychosocial care. “It’s not that I’m a different person. It’s more like I’m becoming the person I was meant to be. And all those layers of trauma and sadness...I’ve been able to shed a lot of that.” – Judy Wight “When I started to learn about psychedelic-assisted therapy, read some of the patient accounts, and see some of the research, I said, ‘I've got to learn about this. I think that this could be another tool that would be useful for people in this space where we don't have the perfect answer, and we don't have the perfect treatments.’” – Jennifer Bires, MSW, LCSW, OSW-C, FACCC “When I give talks around this, I have an iceberg. Above the iceberg I have chemotherapy, surgery, and radiation, and underneath the iceberg I have what’s called psychosocial, psycho-spiritual, psychological care. And I think true cancer care is treating everything in the iceberg, not just what's above the water.” – Manish Agrawal, MD Guests: Jennifer Bires, MSW, LCSW, OSW-C, FACCC Executive Director, Life with Cancer and Patient Experience Inova Health System Fairfax, VA Judy Wight Breast Cancer Survivor Manish Agrawal, MD Cofounder and CEO Sunstone Therapies REKINDLE Investigator This podcast is sponsored by Reunion Neuroscience. Resources: Scan to learn more about the REKINDLE study:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/40013040
info_outline
Set Goals in Today’s Health Care Reality
01/29/2026
Set Goals in Today’s Health Care Reality
Of the barriers to innovation and adopting new strategies, human hesitation is one of the greatest. Health care is a rapidly evolving field by nature, which is compounded by near constant technological advancement. For insight into overcoming hesitation while navigating frequent change in a burnout-oriented industry, CANCER BUZZ spoke with Michelle Rozen, PhD, behavioral scientist, bestselling author, and keynote speaker at the upcoming 2026 ACCC Leadership Summit. Dr. Rozen shares concrete strategies that oncology leaders can implement in their programs to not just survive, but thrive in an unprecedented era of change. “You can’t control change around you. You can’t control change in [your] organization. You can’t control change in the health care industry. You can’t control change in the world...but you are not helpless. There is a way to set goals and actually follow through that gives you a sense of control in this fast-paced, rapidly changing world that we live in.” – Michelle Rozen, PhD Guest: Michelle Rozen, PhD Behavioral scientist and bestselling author Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/39915100
info_outline
Plans for 2026: A Dialogue With ACCC’s Executive Director
01/28/2026
Plans for 2026: A Dialogue With ACCC’s Executive Director
In the second installment of Oncology Unscripted, an unfiltered, honest dialogue about the state of cancer care today, hosts Mark Liu and Deirdre Saulet invite Meagan O’Neill, MS, Executive Director of ACCC, to discuss the Association’s plans for the upcoming year, honing in on challenges and opportunities within its membership. O’Neill shares the vision behind expanding the CANCER BUZZ podcast, the continued development of ACCC’s 2030 vision, and how she views crisis as a path forward for innovation. “When I look at 2026, [I look] at crisis as an opportunity...How can we use this time to try something new and solve some of these problems?” – Meagan O’Neill, MS “Unfortunately, [with] cancer care in this country, the outcomes and experience you [have] are too dependent on who you are, your zip code—even down to the door that you enter and the provider you see...There’s no shortage of opportunities to help programs start chipping away at that.” – Meagan O’Neill, MS Meagan O’Neill, MS Executive Director Association of Cancer Care Centers (ACCC) To submit a topic of discussion to the podcast, please email and . Resources
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/39914885
info_outline
APPs Paving the Way in Leadership
01/20/2026
APPs Paving the Way in Leadership
Advanced practice providers (APPs) are both an integral part of the care team and a driving force behind innovation in oncology. This special state society episode of CANCER BUZZ will explore how oncology APPs are stepping into leadership roles—formally and informally—to advocate for role clarity and equitable compensation, improve mentorship, and elevate the value of APPs within the multidisciplinary cancer care team. Jessica Leibelt, AGNP-C, AOCNP, from Fred Hutchinson Cancer Center, Carlin Callaway, DMP, RN, ACNP-BC, ACNS-BC, AOCNP, from the University of Colorado Cancer Center, and Rachel M Stevenson, PA-C, from ECU Health, will share their real-world experiences of driving systemic change while paving the way for the next generation of APPs. Guests: Jessica Leibelt, AGNP-C, AOCNP Manager, Community Advanced Practice Providers Nurse Practitioner, Hematology Oncology + Oncosexology Fred Hutchinson Cancer Center at UW Medical Center – Northwest Seattle, WA Carlin Callaway, DNP, RN, ACNP-BC, ACNS-BC, AOCNP Assistant Professor, School of Medicine Lead Advanced Practice Provider, Medical Oncology University of Colorado Cancer Center – Anschutz Medical Campus Aurora, CO Rachel M Stevenson, PA-C Physician Assistant ECU Health Greenville, NC “We have a huge role in educating and doing symptom management, but also really creative things like doing APP-led clinics.” - Jessica Leibelt, AGNP-C, AOCNP “It takes a heck of a lot of work to hire people, and it takes even more work to let somebody go when it's not a good fit. So much of what I do is trying to help find [APPs] who will be a good fit for the organization” - Carlin Callaway, DNP, RN, ACNP-BC, AOCNP “Our main goal is the same [as doctors]: to make sure there is excellent health care for all individuals that come to our door. As long as we can work together, I think we can provide great health care.” - Rachel M Stevenson, PA-C This podcast is part of the Optimizing the Role of the APP in Oncology Care program, made possible through the support from the Colorado Oncology Society, Iowa Oncology Society, Empire State Hematology & Oncology Society, Nevada Oncology Society, North Carolina Oncology Association, and Washington State Medical Oncology Society. Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/39798000
info_outline
Training the Next Generation of Oncology Leaders
12/16/2025
Training the Next Generation of Oncology Leaders
Cancer cases, cancer-related deaths, and survivorship are projected to rise exponentially—yet oncology faces critical workforce shortages. In this episode, CANCER BUZZ speaks with Tristan Blanco, a biology major and fellow in VCU Massey’s Cancer-focused Undergraduate Research Experience (CURE) Program, who shares his experience as part of a program designed to scale oncology education and meet the evolving needs of cancer care nationwide. Get behind the scenes of an innovative training model that’s preparing the next generation of oncology leaders. "It’s one of the smartest ways to address the workforce shortage. We’re making sure more students get the chance to discover oncology and have that opportunity.” — Tristan Blanco Tristan Blanco Biology major and fellow in the Cancer-focused Undergraduate Research Experience (CURE) Program VCU Massey Comprehensive Cancer Center Richmond, VA Resources:
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/39424590
info_outline
Introducing Oncology Unscripted
12/10/2025
Introducing Oncology Unscripted
Introducing a brand new podcast from ACCC: Oncology Unscripted. In this inaugural episode, hosts Mark Liu and Deirdre Saulet lay out what listeners can expect from the show, including unfiltered, honest dialogue about the state of cancer care today, the most pressing challenges providers are facing, and how they can move forward with hope amid unpredictable headwinds. Liu and Saulet will approach a variety of topics, from operational to financial to clinical, as they explore how providers can help one another, continue to hold important conversations, and act as agents of change in oncology. "I think about my grandmother who spoke Spanish, Chinese, and English...If she was here, and needed to navigate our health care system with a serious illness or diagnosis of cancer, what would that look like for her? I often put my family members in these scenarios...What would they do? What would I do if I was on the other side?...How can we make a complicated health care system work for everyone?” -- Mark Liu, MHA “We can have all the innovations in the world, but if the people who need them most can’t access them, what’s the point? What are we doing this for?” -- Deirdre Saulet, PhD Mark Liu, MHA Senior Director of Oncology Strategy Transformation & Analytics Mount Sinai Health System Deirdre Saulet, PhD Chief Strategy Officer Jasper Health
/episode/index/show/8c14e234-7a96-47a3-84da-b3cf4f090e2f/id/39348765